Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein.

Literature DB >> 16328600

The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein.

Christine Rebischung¹, Raphaëlle Barnoud, Laetitia Stéfani, Jean-Luc Faucheron, Mireille Mousseau.

Abstract

The c-erbB-2 protein is overexpressed in 7% of gastric cancer cases, suggesting that anti-c-erbB-2 antibody therapy (trastuzumab; Herceptin) could be used. We report here a 28-year-old woman with metastatic gastric cancer overexpressing c-erbB-2 (3 + strong membrane staining on immunohistochemistry) who was treated with trastuzumab in combination with chemotherapy. A complete response was obtained with a combination of trastuzumab and oxaliplatin and was maintained with trastuzumab alone for 18 months. The patient relapsed and chemotherapy (capecitabine, docetaxel) was combined with the anti-c-erbB-2 antibody. The patient survived for 4 years with metastatic disease controlled for 2 years by immunochemotherapy. We conclude that the combination of trastuzumab and chemotherapy is efficient in the treatment of metastatic gastric carcinoma with overexpression of the c-erbB-2 protein.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2005 PMID： 16328600 DOI： 10.1007/s10120-005-0342-7

Source DB: PubMed Journal: Gastric Cancer ISSN： 1436-3291 Impact factor: 7.370

14 in total

1. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.

Authors: H J Burstein; I Kuter; S M Campos; R S Gelman; L Tribou; L M Parker; J Manola; J Younger; U Matulonis; C A Bunnell; A H Partridge; P G Richardson; K Clarke; L N Shulman; E P Winer
Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544

2. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.

Authors: M Nakajima; H Sawada; Y Yamada; A Watanabe; M Tatsumi; J Yamashita; M Matsuda; T Sakaguchi; T Hirao; H Nakano
Journal: Cancer Date: 1999-05-01 Impact factor: 6.860

3. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.

Authors: H Allgayer; R Babic; K U Gruetzner; A Tarabichi; F W Schildberg; M M Heiss
Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544

4. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors: Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544

5. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Authors: M Tanner; M Hollmén; T T Junttila; A I Kapanen; S Tommola; Y Soini; H Helin; J Salo; H Joensuu; E Sihvo; K Elenius; J Isola
Journal: Ann Oncol Date: 2005-02 Impact factor: 32.976

6. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal: Science Date: 1989-05-12 Impact factor: 47.728

7. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay.

Authors: Takuo Takehana; Kazuyoshi Kunitomo; Koji Kono; Fumiaki Kitahara; Hidehiko Iizuka; Yoshiro Matsumoto; Masayuki A Fujino; Akishi Ooi
Journal: Int J Cancer Date: 2002-04-20 Impact factor: 7.396

8. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas.

Authors: K Sakai; S Mori; T Kawamoto; S Taniguchi; O Kobori; Y Morioka; T Kuroki; K Kano
Journal: J Natl Cancer Inst Date: 1986-11 Impact factor: 13.506

Review 9. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review.

Authors: P M Ravdin; G C Chamness
Journal: Gene Date: 1995-06-14 Impact factor: 3.688

10. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.

Authors: T R J Evans; G Pentheroudakis; J Paul; A McInnes; R Blackie; N Raby; R Morrison; G M Fullarton; M Soukop; A C McDonald
Journal: Ann Oncol Date: 2002-09 Impact factor: 32.976

14 in total

1. Antibody-based targeted therapy for gastric cancer.

Authors: Florian Lordick; Christian Peschel; Jörg Rüdiger Siewert
Journal: Gastric Cancer Date: 2005 Impact factor: 7.370

2. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing.

Authors: Zhi Jiang Zang; Choon Kiat Ong; Ioana Cutcutache; Willie Yu; Shen Li Zhang; Dachuan Huang; Lian Dee Ler; Karl Dykema; Anna Gan; Jiong Tao; Siyu Lim; Yujing Liu; P Andrew Futreal; Heike Grabsch; Kyle A Furge; Liang Kee Goh; Steve Rozen; Bin Tean Teh; Patrick Tan
Journal: Cancer Res Date: 2010-11-19 Impact factor: 12.701

Review 3. Locally advanced and metastatic gastric cancer: current management and new treatment developments.

Authors: Kathryn Field; Michael Michael; Trevor Leong
Journal: Drugs Date: 2008 Impact factor: 9.546

Review 4. ERBBs in the gastrointestinal tract: recent progress and new perspectives.

Authors: William H Fiske; David Threadgill; Robert J Coffey
Journal: Exp Cell Res Date: 2008-11-07 Impact factor: 3.905

5. Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma.

Authors: Carlos Gómez-Martín; Angel Concha; José María Corominas; Tomás García-Caballero; Elena García-García; Mar Iglesias; José Antonio López; Santiago Ramón y Cajal; Federico Rojo; José Palacios; Francisco Vera-Sempere; Enrique Aranda; Ramon Colomer; Pilar García-Alfonso; Pilar Garrido; Fernando Rivera; Fernando López-Ríos
Journal: Clin Transl Oncol Date: 2011-09 Impact factor: 3.405